Analysis links SERMs to breast cancer prevention benefit

05/1/2013 | MyHealthNewsDaily.com · PhysiciansBriefing.com

Taking selective estrogen receptor modulators such as tamoxifen and raloxifene after menopause reduces by 38% a woman's risk of developing any kind of breast cancer for 10 years, according to an analysis of data from nine studies. The estrogen-blocking drugs particularly lowered the risk of estrogen-receptor positive breast cancer, researchers found. The study appeared online in The Lancet.

View Full Article in:

MyHealthNewsDaily.com · PhysiciansBriefing.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD